NexMed Announces Presentation of Data at the 67th Annual Meeting of the American Academy of Dermatology
NVS | Quote | Chart | News | PowerRating -- NexMed, Inc. (Nasdaq: NEXM | Quote | Chart | News | PowerRating), a developer of products based on the NexACT(R)
drug delivery technology, today announced that four presentations on
preclinical and clinical studies of NM100060, a topical onychomycosis
(nail fungus) investigative drug product, will be made at the 67th
Annual Meeting of the American Academy of Dermatology (AAD), in San
Francisco, CA from March 6-10, 2009.
NM100060 is a topical application of terbinafine hydrochloride utilizing
NexACT, NexMed's patented permeation enhancer technology, and is
licensed to Novartis Pharma AG for global development.
About NexMed
NexMed, Inc. leverages its proprietary NexACT drug delivery technology
to develop innovative topical pharmaceutical products that address unmet
medical needs. NexMed's pipeline also includes its late stage
alprostadil treatment for erectile dysfunction, a Phase 2 treatment for
female sexual arousal disorder, and an early stage treatment for
psoriasis. For further information about NexMed, go to www.nexmed.com.
SOURCE: NexMed, Inc.
NexMed, Inc.
Mark Westgate, CFO, 609-371-8123, ext: 159
mwestgate@nexmed.com
or
Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com
For full details on Novartis Ag Ads (NVS) NVS. Novartis Ag Ads (NVS) has Short Term PowerRatings at TradingMarkets. Details on Novartis Ag Ads (NVS) Short Term PowerRatings is available at This Link.
For full details on Nexmed Inc (NEXM) NEXM. Nexmed Inc (NEXM) has Short Term PowerRatings at TradingMarkets. Details on Nexmed Inc (NEXM) Short Term PowerRatings is available at This Link.
- Debiopharm Group signs agreement with Novartis for Debio 025 - 02/09/10
- BiomedReports: News and FDA Updates for Lannett (NYSE:LCI), MWI (NASDAQ:MWIV), NexMed (Nasdaq:NEXM) - 02/09/10
- Liberty Analytics Co. Initiates Independent Research Coverage on NexMed, Inc. - 02/09/10
- SciClone and Sigma-Tau reports positive results from influenza vaccine study - 02/09/10
- Debiopharm Group signs licensing agreement with Novartis for Debio 025 for hepatitis C - 02/09/10
- More News >>


